alexa First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen.
Immunology

Immunology

Immunological Disorders & Immunotherapy

Author(s): Gu SY, Huang TM, Ruan L, Miao YH, Lu H,

Abstract Share this page

Abstract In the absence of a truly representative animal model, the question of whether EBV-related diseases can be prevented by a vaccine has been studied for the first time in humans. A live recombinant virus based on the licensed vaccinia strain Tien Tan, expressing under the 11K vaccinia promoter the major EBV membrane antigen BNLF-1 MA (gp 220-340), was constructed and tested in three different human populations: EBV-positive and vaccinia-virus-exposed adults; EBV-positive, non-vaccinia-virus-exposed juveniles; and EBV and vaccinia virus-naive infants. No significant titre variations for EBV were observed in the adults, but EBV-neutralising titres increased in the vaccinated juveniles, while antibodies to VCA of EBV remained unchanged. All nine vaccinated infants developed antibodies to MA (membrane antigen) with neutralising properties in vitro; three of these infants were infected by EBV via natural routes over a period of 16 months after vaccination and all ten unvaccinated control infants became infected. It has been shown for the first time that protection against and/or delay of EBV infection by the natural route is possible in humans and that live vaccinia vectors can be used and are efficacious.
This article was published in Dev Biol Stand and referenced in Immunological Disorders & Immunotherapy

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 7th World Congress on Immunology
    September 11-12, 2017 Amsterdam, Netherlands
  • 3rd International Congress on Neuroimmunology and Therapeutics
    November 2-3, 2017 Atlanta, Georgia, USA
  • 2nd International Conference on Autoimmunity
    November 06-07, 2017 Frankfurt, Germany
  • World Immunology Congress
    Dec 14-15, 2017 Dubai, UAE

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords